candesartan has been researched along with 20-hydroxy-5,8,11,14-eicosatetraenoic acid in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hoagland, KM; Ito, O; Ito, S; Omata, K; Roman, RJ | 1 |
| Hu, G; Ito, O; Kohzuki, M; Miura, T; Muroya, Y; Ogawa, Y; Rong, R; Wang, W | 1 |
2 other study(ies) available for candesartan and 20-hydroxy-5,8,11,14-eicosatetraenoic acid
| Article | Year |
|---|---|
Effects of converting enzyme inhibitors on renal P-450 metabolism of arachidonic acid.
Topics: 8,11,14-Eicosatrienoic Acid; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Arachidonic Acid; Benzimidazoles; Biphenyl Compounds; Bradykinin; Bradykinin Receptor Antagonists; Captopril; Cytochrome P-450 CYP4A; Cytochrome P-450 Enzyme System; Desoxycorticosterone; Enalapril; Enzyme Inhibitors; Hydroxyeicosatetraenoic Acids; Kidney; Kidney Cortex; Kidney Medulla; Male; Microsomes; Mixed Function Oxygenases; NADPH-Ferrihemoprotein Reductase; NG-Nitroarginine Methyl Ester; Nitric Oxide Synthase; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Spironolactone; Tetrazoles | 2001 |
Angiotensin II upregulates CYP4A isoform expression in the rat kidney through angiotensin II type 1 receptor.
Topics: Angiotensin II; Animals; Arachidonic Acid; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Cytochrome P-450 CYP4A; Disease Models, Animal; Gene Expression Regulation; Humans; Hydroxyeicosatetraenoic Acids; Hypertension; Kidney; Protein Isoforms; Rats; Receptor, Angiotensin, Type 1; RNA, Messenger; Tetrazoles | 2018 |